Fig. 4

Forest plots of serious adverse events comparing tocilizumab combination therapy (TCZ _COMBI ) with tocilizumab monotherapy (TCZ _MONO ) (a), TCZ _COMBI with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) (b) and TCZ_MONO with a csDMARD (c)